It does not currently serve Alabama, Alaska, Arkansas, Hawaii, Massachusetts, Missouri, New Mexico, New York, South Carolina, or Virginia
however, in late 2024 and early 2025 the drug manufacturers and federal regulators finally decided it was time to start fighting back and end this Wild West era (this was never supposed to be a Wild West film anyways)
Providers offering 'one-size-fits-all' dosing or rapid titration schedules ignore these critical variables
Tirzepatide (dual GIP and GLP-1 agonist) 4
Hypoglycemia Due to Medication Errors: Accidental mix-ups between insulin products have been reported
- Administration: Subcutaneous injection